Severe cytomegalovirus (CMV) community-acquired pneumonia (CAP) in a nonimmunocompromised host
Cunha BA, Pherez F and Walls N. Severe cytomegalovirus (CMV) community-acquired pneumonia (CAP) in a nonimmunocompromised host. Heart & Lung 2009; 38: 243-248.
Cytomegalovirose acquise de l'adulte immunocompetent 116 observations
Faucher JF, Abraham B, Segondy M, et al. Acquired cytomegalovirus infections in immunocompetent adults. Presse Med 1998; 27: 1774-1779. (Pubitemid 28530862)
Severe cytomegalovirus infection in immunocompetent patients
Eddlestone M, Peacock S, Juniper M, et al. Severe cytomegalovirus infection in immunocompetent patients. Clinical Infectious Diseases 1997; 24: 52-56. (Pubitemid 27023672)
Parenteral ganciclovir treatment of acute CMV infection in the immunocompetent host
DOI 10.1007/BF02113508
Laing RBS, Dykhuizen RS, Smith CC, et al. Parenteral ganciclovir treatment of acute CMV infection in the immunocompetent host. Infection 1997; 25(1): 44-46. (Pubitemid 27075660)
Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients
Asberg A, Humar A, Jardine AG, et al. Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients. Am J Transplant. 2009; 9(5): 1205-1213.
Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: Successful treatment with oral valganciclovir
Fernandez-Ruiz M, Munoz-Codoceo C, Lopez-Medrano F, et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med. 2008; 47(22): 1963.